A.S. Skotnikov , V.D. Zakiev , A.D. Gvozdev , V.V. Lazareva
Abstract
Beta-blockers are currently one of the most prescribed drugs in various acute and chronic conditions due to wide range of indications and a large evidence base. Metoprolol succinate (Betaloc ZOK) is one of modern lipophilic β1-selective blocker without intrinsic sympathomimetic activity and available in controlled slow release (CR/XL) form. Metoprolol succinate CR/XL can be considered an essential treatment of a wide range of cardiovascular and other diseases (for example, migraine and thyrotoxicosis). However, this drug is often used in not optimal doses. The purpose of this article is to draw the attention of physicians to the unjustified underestimation of β-AB doses in a number of clinical conditions.
Keywords: beta-blockers, target doses, indications, comorbidity, metoprolol succinate.
Keywords: beta-blockers, target doses, indications, comorbidity, metoprolol succinate.
About the Author
A.S. Skotnikov 1 , V.D. Zakiev 2 , A.D. Gvozdev 3 , V.V. Lazareva 41 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
2 Russian Gerontological Scientific and Clinical Center – branch of Pirogov Russian National Research Medical University, Moscow, Russia
3 Davydovsky City Clinical Hospital, Moscow, Russia
4 Russian State Social University, Moscow, Russia
References
1. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 12th Edition.
2. Кукес В.Г., Сычев Д.А., Андреев Д.А. Клиническая фармакология β-адреноблокаторов. РМЖ. 2005;14:932. Kukes V.G., Sychev D.A., Andreev D.A. Clinical pharmacology of b-adrenoblockers. Breast cancer. Russian Medical Journal. 2005;14:932 (in Russian).
3. Sandberg A, Ragnarsson G, Jonsson UE, Sjögren J. Design of a new multiple-unit controlled-release formulation of metoprolol—metoprolol CR. Eur J Clin Pharmacol 1988;33(Suppl):S3-7. DOI: 10.1007/ BF00578405
4. Sorbets E, Steg PG, Young R. et al. CLARIFY investigators. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J 2019;40(18):1399-1407. DOI: 10.1093/eurheartj/ehy811
5. White CM. Prevention of suboptimal beta-blocker treatment in patients with myocardial infarction. Ann Pharmacother 1999;33(10):1063-72. DOI: 10.1345/aph.18395
6. Eriksen-Volnes T, Westheim A, Gullestad L. et al. β-Blocker Doses and Heart Rate in Patients with Heart Failure: Results from the National Norwegian Heart Failure Registry. Biomed Hub 2020;5(1):9-18. DOI: 10.1159/000505474
7. McGinlay M, Straw S, Byrom-Goulthorp R et al. Suboptimal Dosing of β-Blockers in Chronic Heart Failure: A Missed Opportunity? J Cardiovasc Nurs 2022;37(6):589-594. DOI: 10.1097/JCN.00000000 00000847
8. Бубнова М.Г. Место β-адреноблокаторов в лечении сердечно-сосудистых заболеваний с позиции современных рекомендаций: в фокусе метопролола сукцинат CR/XL. CardioСоматика. 2022;13 (1):51-62. DOI: 10.17816/22217185.2022.1.201712 Bubnova M.G. Current guidelines for β-adrenoblockers use in cardiovascular diseases: focus on metoprolol succinate CR/XL: A review. Cardiosomatics. 2022;13(1):51-62. DOI: 10.17816/22217185.2022. 1.201712 (in Russian).
9. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Рос. кардиол. журн. 2020;25(3):3786. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. DOI: 10.15829/1560-4071-2020-3-3786 11 (in Russian).
10. Williams B, Mancia G, Spiering W et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. DOI: 10.1093/eurheartj/ehy339. Erratum in: Eur Heart J. 2019;40(5):475. DOI: 10.1093/eurheartj/ehy686
11. Mancia G, Kreutz R, Brunström M. et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. DOI: 10.1097/HJH.0000000000003480. Erratum in: J Hypertens. 2024;42(1):194. DOI: 10.1097/HJH.0000000000003621
12. McEvoy JW, McCarthy CP, Bruno RM. et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024:ehae178. DOI: 10.1093/eurheartj/ehae178
13. Wikstrand J, Warnold I, Olsson G et al. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA. 1988;259(13):1976-82.
14. Luomanmäki K, Inkovaara J, Hartikainen M et al. Efficacy and tolerability of isradipine and metoprolol in treatment of hypertension: the Finnish Isradipine Study in Hypertension (FISH). J Cardiovasc Pharmacol 1992;20(2):296-303. DOI: 10.1097/00005344-199208000-00016
15. Morales-Salinas A, Kones R. Concerning the degradation of β-blocker use in the 2018 ESC/ESH hypertension guidelines. Eur Heart J 2019;40(25):2091. DOI: 10.1093/eurheartj/ehz125
16. Virani SS, Newby LK, Arnold SV. et al. 2023 AHA/ACC/ACCP/ ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 2023;148(9):e9-e119.
17. Knuuti J, Wijns W, Saraste A. et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41(3):407-477. DOI: 10.1093/eurheartj/ehz425. Erratum in: Eur Heart J 2020;41 (44):4242. DOI: 10.1093/eurheartj/ehz825
18. Российское кардиологическое общество (РКО) Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Рос. кардиол. журн. 2020;25(11):4076. Russian Society of Cardiology (RSC) 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076 (in Russian).
19. Ekelund LG, Olsson AG, Orö L, Rössner S. Effects of the cardioselective beta-adrenergic receptor blocking agent metoprolol in angina pectoris. Subacute study with exercise tests. Br Heart J 1976;38(2):155-61. DOI: 10.1136/hrt.38.2.155
20. Narahara KA. Double-blind comparison of once daily betaxolol versus propranolol four times daily in stable angina pectoris. Betaxolol Investigators Group. Am J Cardiol. 1990;65(9):577-82. DOI: 10.1016/0002-9149(90)91033-3
21. Frishman WH, Heiman M, Soberman J et al. Comparison of celiprolol and propranolol in stable angina pectoris. Celiprolol International Angina Study Group. Am J Cardiol 1991;67(8):665-70. DOI: 10.1016/0002-9149(91)90518-p
22. Arnman K, Rydén L. Comparison of metoprolol and verapamil in the treatment of angina pectoris. Am J Cardiol 1982;49(4):821-7. DOI: 10.1016/0002-9149(82)91964-6
23. Ahuja RC, Sinha N, Kumar RR, Saran RK. Effect of metoprolol and diltiazem on the total ischaemic burden in patients with chronic stable angina: a randomized controlled trial. Int J Cardiol 1993;41(3):191-9. DOI: 10.1016/0167-5273(93)90115-w
24. Ardissino D, Savonitto S, Egstrup K et al. Transient myocardial ischemia during daily life in rest and exertional angina pectoris and comparison of effectiveness of metoprolol versus nifedipine. Am J Cardiol 1991;67(11):946-52. DOI: 10.1016/0002-9149(91)90165-h
25. Heidenreich PA, McDonald KM, Hastie T. et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999;281(20):1927-36. DOI: 10.1001/jama.281.20.1927
26. Vrints C, Andreotti F, Koskinas KC. et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024:ehae177. DOI: 10.1093/eurheartj/ehae 177
27. Bassan M. Chronic Stable Angina. N Engl J Med. 2016;375(3):292-3. DOI: 10.1056/NEJMc1605394
28. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26(10):967-74. DOI: 10.1093/eurheartj/ ehi190
29. Fox K, Ford I, Steg PG et al. SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014;371(12):1091-9. DOI: 10.1056/NEJMoa1406430
30. Bangalore S, Steg G, Deedwania P. et al. REACH Registry Investigators. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012;308(13):1340-9. DOI: 10.1001/jama.2012.12559
31. Motivala AA, Parikh V, Roe M et al. Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry. JACC Cardiovasc Interv 2016;9(16):1639-48. DOI: 10.1016/j.jcin.2016.05.048
32. Bangalore S, Bhatt DL, Steg PG et al. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes 2014;7(6):872-81. DOI: 10.1161/CIRCOUTCOMES.114.001073
33. Zhang H, Yuan X, Zhang H et al. Efficacy of Long-Term β-Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery. Circulation 2015;131(25):2194-201. DOI: 10.1161/CIRCULATIONAHA.114.014209
34. Uusitalo A, Keyriläinen O, Johnsson G. A dose-response study on metoprolol in angina pectoris. Ann Clin Res 1981;13(30):54-7
35. Толпыгина С.Н., Марцевич С.Ю. Эффективность и безопасность высоких доз метопролола пролонгированного действия при лечении пациентов со стабильным течением ишемической болезни сердца. Рациональная фармакотерапия в кардиологии. 2008;5: 46-52 Tolpygina SN, Martsevich SY. Efficacy and safety of metoprolol succinate in high doses in patients with stable course of ischemic heart disease. Ratsional’naia farmakoterapiia v kardiologii. 2008;5:46-52. DOI: 10.20996/1819-6446 (in Russian).
36. Egstrup K, Gundersen T, Härkönen R et al. The antianginal efficacy and tolerability of controlled-release metoprolol once daily: a comparison with conventional metoprolol tablets twice daily. Eur J Clin Pharmacol 1988;33(l):S45-9. DOI: 10.1007/BF00578412
37. Sandberg A, Blomqvist I, Jonsson UE et al. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. Eur J Clin Pharmacol 1988;33(Suppl.):S9-14. DOI: 10.1007/BF00578406
38. Freemantle N, Cleland J, Young P et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318(7200):1730-7. DOI: 10.1136/bmj.318.7200.1730
39. Evans T, Stewart R. Should beta-blockers be recommended after myocardial infarction when left ventricular ejection fraction is normal? Heart 2023;109(15):1128-1129. DOI: 10.1136/heartjnl-2023-322544
40. Bangalore S, Makani H, Radford M et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med 2014;127(10):939-53. DOI: 10.1016/j.amjmed. 2014. 05.032.
41. Ibanez B, Macaya C, Sánchez-Brunete V et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation 2013;128(14):1495-503. DOI: 10.1161/CIRCULATIONAHA.113.003653
42. García-Prieto J, Villena-Gutiérrez R, Gómez M. et al. Neutrophil stunning by metoprolol reduces infarct size. Nat Commun. 2017;8:14780. DOI: 10.1038/ncomms14780
43. Pizarro G, Fernández-Friera L, Fuster V et al. Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). J Am Coll Cardiol 2014;63(22):2356-62. DOI: 10.1016/j.jacc. 2014.03.014
44. Roolvink V, Ibáñez B, Ottervanger JP et al. EARLY-BAMI Investigators. Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. J Am Coll Cardiol 2016;67(23):2705-2715. DOI: 10.1016/ j.jacc.2016.03.522
45. García-Ruiz JM, Fernández-Jiménez R, García-Alvarez A. et al. Impact of the Timing of Metoprolol Administration During STEMI on Infarct Size and Ventricular Function. J Am Coll Cardiol. 2016;67(18):2093-2104. DOI: 10.1016/j.jacc.2016.02.050
46. Hoedemaker NP, Roolvink V, de Winter RJ et al. Early intravenous beta-blockers in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A patient-pooled meta-analysis of randomized clinical trials. Eur Heart J Acute Cardiovasc Care 2020;9(5):469-477. DOI: 10.1177/2048872619 830609.
47. Byrne RA, Rossello X, Coughlan JJ et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. DOI: 10.1093/eurheartj/ehad191. Erratum in: Eur Heart J 2024;45(13):1145. DOI: 10.1093/eurheartj/ehad870.
48. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357(9266):1385-90. DOI: 10.1016/s0140-6736(00)04560-8.
49. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-7
50. Watanabe H, Ozasa N, Morimoto T et al. CAPITAL-RCT investigators. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS One. 2018;13(8):e0199347. DOI: 10.1371/journal.pone. 0199347
51. Yndigegn T, Lindahl B, Mars K et al. REDUCE-AMI Investigators. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med 2024;390(15):1372-1381. DOI: 10.1056/NEJM oa2401479
52. Steg PG. Routine Beta-Blockers in Secondary Prevention – On Injured Reserve. N Engl J Med 2024;390(15):1434-1436. DOI: 10.1056/NEJMe2402731
53. Silvain J, Cayla G, Ferrari E et al. ABYSS Investigators of the ACTION Study Group. Beta-Blocker Interruption or Continuation after Myocardial Infarction. N Engl J Med. 2024. DOI: 10.1056/NEJMoa2404204
54. Закиев В.Д., Воробьёва Н.М., Малая И.П., и др. Бета-адреноблокаторы при хронической сердечной недостаточности с сохранной фракцией выброса левого желудочка: возможен ли депрескрайбинг? Рациональная Фармакотерапия в Кардиологии. 2023;19 (6):607-613. DOI: 10.20996/1819-6446-2023-2987 Zakiev VD, Vorobyeva NM, Malaya IP et al. Beta-blockers in chronic heart failure with preserved left ventricular ejection fraction: is deprescribing possible? Rational Pharmacotherapy in Cardiology. 2023;19(6):607-613 (in Russian).
55. Silverman DN, Plante TB, Infeld M et al. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial. JAMA Netw Open 2019;2(12):e1916598. DOI: 10.1001/jamanetworkopen.2019. 16598.
56. Kristensen AMD, Munkhaugen J, Halvorsen S et al. The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics. Eur Heart J Cardiovasc Pharmacother. 2024;10(3):175-183. DOI: 10.1093/ehjcvp/ pvad093
57. Vetrano A, Vetrano D, Pariggiano I. P208 the treatment with beta-blockers after myocardial infarction without reduced ejection fraction (REBOOT) trial. Current status. Eur Heart J Suppl. 2022;24(Suppl. C):suac012.200. DOI: 10.1093/eurheartj/suac012.200
58. URL: https://clinicaltrials.gov/study/NCT04769362
59. URL: https://clinicaltrials.gov/study/NCT05081999
60. Heidenreich PA, Bozkurt B, Aguilar D et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology. American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145(18):e895-e1032. DOI: 10.1161/CIR.0000000000001063
61. McDonagh TA, Metra M, Adamo M et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42(36):3599-3726. DOI: 10.1093/eurheartj/ehab368
62. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Рос. кардиол. журн. 2020;25(11):4083. DOI: 10.15829/1560-4071-2020-4083.2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083 (in Russian).
63. Maddox TM, Januzzi JL Jr, Allen LA et al. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2024;83(15):1444-1488. DOI: 10.1016/j.jacc.2023.12.024
64. McAlister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009;150(11):784-94. DOI: 10.7326/0003-4819-150-11-200906020-00006.
65. Swedberg K, Komajda M, Böhm M et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-85. DOI: 10.1016/S0140-6736(10)61198-1. Erratum in: Lancet 2010;376(9757):1988
66. Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013;102(1):11-22. DOI: 10.1007/s00392-012-0467-8
67. Mebazaa A, Davison B, Chioncel O et al. G. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 2022;400(10367):1938-1952. DOI: 10.1016/S0140-6736(22)02076-1
68. Čelutkienė J, Čerlinskaitė-Bajorė K, Cotter G et al. Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial. Circ Heart Fail 2024;17(4): e011221. DOI: 10.1161/CIRCHEARTFAILURE.123.011221
69. Smarz K, Tysarowski M, Zaborska B et al. Chronotropic Incompetence Limits Aerobic Exercise Capacity in Patients Taking Beta-Blockers: Real-Life Observation of Consecutive Patients. Healthcare (Basel) 2021;9(2):212. DOI: 10.3390/healthcare9020212
70. Palau P, Seller J, Domínguez E et al. Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol 2021;78(21):2042-2056. DOI: 10.1016/j.jacc.2021. 08.073
71. Бокерия Л.А., Голухова Е.З., Попов С.В. и др. Российское кардио-логическое общество. Наджелудочковые тахикардии у взрослых. Клинические рекомендации 2020. Рос. кардиол. журн. 2021; 26(5):4484. DOI: 10.15829/1560-4071-2021-4 Bokeria LA, Golukhova EZ, Popov SV et al. Russian Society of Cardiology. 2020 Clinical practice guidelines for Supraventricular tachycardia in adults. Russian Journal of Cardiology 2021;26(5):4484. DOI: 10.15829/1560-4071-2021-4 (in Russian).
72. Hindricks G, Potpara T, Dagres N et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI: 10.1093/eurheartj/ehaa612. Erratum in: Eur Heart J. 2021;42(5):507. DOI: 10.1093/eurheartj/ehaa798. Erratum in: Eur Heart J. 2021;42(5):546-547. DOI: 10.1093/eurheartj/ ehaa945. Erratum in: Eur Heart J. 2021;42(40):4194. DOI: 10.1093/ eurheartj/ehab648
73. Van Gelder IC, Rienstra M, Bunting KV et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Aug 30:ehae176. DOI: 10.1093/eurheartj/ehae176
74. Лебедев Д.С., Михайлов Е.Н., Неминущий Н.М. и др. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020. Рос. кардиол. журн. 2021;26(7):4600. Lebedev DS, Mikhailov EN, Neminuschiy NM et al. 2020 Clinical guidelines. Russian Journal of Cardiology. 2021;26(7):4600. DOI: 10.15829/1560-4071-2021-4600 (in Russian).
75. Kühlkamp V, Schirdewan A, Stangl K et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000;36(1):139-
For citation:Skotnikov A.S., Zakiev V.D., Gvozdeva A.D., Lazareva V.V. The choice of dosage regimen of modern beta-blockers in different clinical situations (using the example of metoprolol succinate). Clinical review for general practice. 2024; 5 (10): 52–63 (In Russ.). DOI: 10.47407/kr2024.5.10.00496
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
